Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
CD3xCD20 bispecifics in transformed Waldenström/lymphoplasmacytic lymphoma show estimated PFS @ 6 and 12 months of 59% and 51%, estimated OS rates of 79% and 57%; 15 pts (75%) experienced CRS (5% G3), 15% had ICANS (0% G3–4).”
Title: CD3xCD20 bispecific antibodies in transformed Waldenström macroglobulinemia/lymphoplasmacytic lymphoma
Authors: Morgane Brocard, Damien Roos-Weil, Lukshe Kanagaratnam, Thomas Hueso, Lucile Bussot, Benjamin Papoular, Cécile Tomowiak, Steeve Chevreux, Gilles Crochet, Tristan Vaugeois, Elise Toussaint, Simone Ferrero, Charalampia Kyriakou, Anne Quinquenel, Prashant Kapoor, Eric Durot
You can read the Full Article in HemaSpher.
You can find other articles featuring Robert Orlowski on OncoDaily.
